Xiaoying Zhao

ORCID: 0000-0003-3728-306X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Gastric Cancer Management and Outcomes
  • Viral-associated cancers and disorders
  • Immune Cell Function and Interaction
  • CNS Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • CAR-T cell therapy research
  • Pancreatic and Hepatic Oncology Research
  • RNA modifications and cancer
  • Protein Degradation and Inhibitors
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Cancer-related Molecular Pathways
  • Congenital Diaphragmatic Hernia Studies
  • Bone health and treatments
  • Acute Myeloid Leukemia Research
  • Cancer Genomics and Diagnostics
  • Blood Coagulation and Thrombosis Mechanisms
  • Systemic Lupus Erythematosus Research
  • Metabolism, Diabetes, and Cancer
  • Cancer Immunotherapy and Biomarkers
  • Ubiquitin and proteasome pathways
  • Nutrition and Health in Aging
  • Cancer Diagnosis and Treatment

Fudan University Shanghai Cancer Center
2014-2025

Southwest Medical University
2025

Guangxi Medical University
2025

Hebei University of Chinese Medicine
2025

Handan College
2022-2025

Second Affiliated Hospital of Zhejiang University
2011-2024

Hunan University
2023

Jinan University
2022

Xi'an Jiaotong University
2022

Shanghai Medical College of Fudan University
2015-2021

CD5 is a pan-T-cell surface marker and rarely expressed in diffuse large B-cell lymphoma (DLBCL). Large-scale studies of de novo CD5+ DLBCL are lacking Western countries. In this study by the Rituximab-CHOP Consortium, was 5.5% 879 patients from associated with higher frequencies >1 ECOG performance status, bone marrow involvement, central nervous system relapse, activated B-cell-like subtype, Bcl-2 overexpression, STAT3 NF-κB activation, whereas single-stranded DNA-binding protein 2...

10.18632/oncotarget.3479 article EN Oncotarget 2015-03-08

// Jiayu Chen 1,2,* , Zijun Y. Xu-Monette 2,* Lijuan Deng 2 Qi Shen Ganiraju C. Manyam 3 Azahara Martinez-Lopez 4 Li Zhang Santiago Montes-Moreno Carlo Visco 5 Alexandar Tzankov 6 Lihui Yin Karen Dybkaer 7 April Chiu 8 Attilio Orazi 9 Youli Zu 10 Govind Bhagat 11 Kristy L. Richards 12 Eric D. Hsi 13 William W.L. Choi 14 J. Han van Krieken 15 Jooryung Huh 16 Maurilio Ponzoni 17 Andrés J.M. Ferreri Xiaoying Zhao 18 Michael B. Møller 19 John P. Farnen 20 Jane N. Winter 21 Miguel...

10.18632/oncotarget.3343 article EN Oncotarget 2015-01-21

Abstract Purpose: Activated signal transducer and activator of transcription 3 (STAT3) regulates tumor growth, invasion, cell proliferation, angiogenesis, immune response, survival. Data regarding expression phosphorylated (activated) STAT3 in diffuse large B-cell lymphoma (DLBCL) the impact (pSTAT3) on prognosis are limited. Experimental Design: We evaluated pSTAT3 de novo DLBCL using immunohistochemistry, gene profiling (GEP), set enrichment analysis (GSEA). Results were analyzed...

10.1158/1078-0432.ccr-14-0683 article EN Clinical Cancer Research 2014-08-15

167 Background: The irinotecan based chemotherapy in combination with bevacizumab had become the standard second-line treatment for metastatic colorectal cancer (mCRC), but efficacy was limited. Anlotinib, an oral anti-angiogenic tyrosine kinase inhibitor, initially shown promising clinical effects when combined first-line of mCRC. Whether anlotinib could bring benefit second line warrants further exploration. PD-1 antibody might have partial agents or without first- and third-line...

10.1200/jco.2025.43.4_suppl.167 article EN Journal of Clinical Oncology 2025-01-27

334 Background: For initially unresectable locally advanced or metastatic gastric gastroesophageal junction adenocarcinoma, the prognosis is poor and chemotherapy main treatment option. The AIO-FLOT3 Trial suggested that conversion therapy might improve outcome in pts with limited cancer (GC). We conducted this prospective, single-arm, phase II trial to efficacy of PD-1 inhibitor Cam combined Nab-POF regimen (nab-paclitaxel , oxaliplatin, fluorouracil) adenocarcinoma. Methods: Eligible...

10.1200/jco.2025.43.4_suppl.334 article EN Journal of Clinical Oncology 2025-01-27

Lung ultrasonography (LUS) is increasingly used to assess pulmonary diseases due its safety and convenience. This study aimed find out the association between LUS score PaO2/FiO2 ratio in neonatal pneumonia. prospectively enrolled 57 neonates with suspected (range 0-48) was evaluated by assessing 12 lung regions. The calculated dividing arterial oxygen partial pressure fraction of inspired from blood gas analysis. Correlations were analyzed using Pearson's correlation coefficient. Birth...

10.1002/jcu.23928 article EN Journal of Clinical Ultrasound 2025-01-31

To investigate the effects of a cognitive load theory (CLT)-based WeChat training platform on reducing barriers to reporting adverse events among clinical nurses. In total, 400 nurses from tertiary general hospital were randomized into experimental and control groups (200 each). The group used CLT-based platform, whereas received conventional for nursing events. Both interventions lasted 12 weeks. Barriers reporting, awareness, intention, habit scores compared between groups. After dropouts,...

10.2147/rmhp.s482233 article EN cc-by-nc Risk Management and Healthcare Policy 2025-03-01

The present study analyzed Type 2 diabetes mellitus (T2D)-related gene polymorphisms and their impacts on chemotherapeutic response survival in patients with metastatic gastric cancer (MGC).This retrospective enrolled 108 MGC treated first-line EOF chemotherapy (epirubicin, oxaliplatin 5-fluorouracil combination chemotherapy). Eleven single nucleotide of five T2D-related genes were determined.Among the 11 polymorphisms, three (IGF2BP2 rs4402960, IGF2BP2 rs6769511 KCNQ1 rs163182)...

10.2217/pgs.15.49 article EN Pharmacogenomics 2015-06-01
Coming Soon ...